Jon Paul Gockerman, MD

Professor Emeritus of Medicine
Campus mail 25154 Morris Bldg, Durham, NC 27710
Phone (919) 684-8964
Email address gocke002@mc.duke.edu

My research effort is involved in clinical research studies through the CALGB as well as several sub interests. My interest is the use of 131I MIBG in the treatment of carcinoids. We have completed a dose seeking study to determine the maximum tolerated dose. This has been completed and this paper is in preparation for publication. We plan to do an additional study of randomization in patients with this agent to see if we can determine an objective response rate in a controlled group of patients.

The secondary issue is that of high dose chemotherapy in lymphoma. We have completed a study involving use of high dose chemotherapy in a transplant setting in patients with refractory lymphoma. This study has treated over 100 patients and is in the process of being written up.

Education and Training

  • M.D., The University of Chicago, 1967

Publications

Persons, D. A., M. Laughlin, D. Tanner, J. Perfect, J. P. Gockerman, and J. W. Hathorn. “Fluconazole and Candida krusei fungemia.” N Engl J Med 325, no. 18 (October 31, 1991): 1315.

PMID
1922232
Scholars@Duke

Higa, G. M., J. P. Gockerman, A. L. Hunt, M. R. Jones, and B. J. Horne. “The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.” Cancer 68, no. 8 (October 15, 1991): 1691–93. https://doi.org/10.1002/1097-0142(19911015)68:8<1691::aid-cncr2820680805>3.0.co;2-w.

PMID
1913509
Full Text

Brizel, D. M., E. P. Winer, L. R. Prosnitz, J. Scott, J. Crawford, J. O. Moore, and J. P. Gockerman. “Improved survival in advanced Hodgkin's disease with the use of combined modality therapy.” Int J Radiat Oncol Biol Phys 19, no. 3 (September 1990): 535–42. https://doi.org/10.1016/0360-3016(90)90478-3.

PMID
2211201
Full Text

Jones, R. B., E. J. Shpall, J. Shogan, M. L. Affronti, D. Coniglio, L. Hart, E. Halperin, J. D. Iglehart, J. Moore, and J. Gockerman. “The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.” Cancer 66, no. 3 (August 1, 1990): 431–36. https://doi.org/10.1002/1097-0142(19900801)66:3<431::aid-cncr2820660305>3.0.co;2-x.

PMID
2364358
Full Text

Laszlo, J., D. Goldstein, J. Gockerman, L. Hood, A. T. Huang, P. Triozzi, W. D. Sedwick, H. Koren, E. H. Ellinwood, and C. Y. Tso. “Phase I studies of recombinant interferon-gamma.” J Biol Response Mod 9, no. 2 (April 1990): 185–93.

PMID
2160521
Scholars@Duke

Kaufman, P. A., J. P. Gockerman, and C. S. Greenberg. “Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature.” Am J Med 86, no. 5 (May 1989): 612–16. https://doi.org/10.1016/0002-9343(89)90396-3.

PMID
2712070
Full Text

Borowitz, M. J., J. P. Gockerman, J. O. Moore, C. I. Civin, S. O. Page, J. Robertson, and S. H. Bigner. “Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia.” Am J Clin Pathol 91, no. 3 (March 1989): 265–70. https://doi.org/10.1093/ajcp/91.3.265.

PMID
2646903
Full Text

Peters, W. P., A. Stuart, M. Klotman, C. Gilbert, R. B. Jones, E. J. Shpall, J. Gockerman, R. C. Bast, and J. O. Moore. “High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.” Cancer Chemother Pharmacol 23, no. 6 (1989): 377–83. https://doi.org/10.1007/BF00435840.

PMID
2653660
Full Text

Peters, W. P., E. J. Shpall, R. B. Jones, G. A. Olsen, R. C. Bast, J. P. Gockerman, and J. O. Moore. “High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.” J Clin Oncol 6, no. 9 (September 1988): 1368–76. https://doi.org/10.1200/JCO.1988.6.9.1368.

PMID
3047332
Full Text

Olsen, G. A., J. P. Gockerman, R. C. Bast, M. Borowitz, and W. P. Peters. “Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support.” Transplantation 46, no. 1 (July 1988): 57–60. https://doi.org/10.1097/00007890-198807000-00009.

PMID
3293287
Full Text

Pages